Lv1
60 积分 2023-11-08 加入
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
26天前
已完结
Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study
1个月前
已完结
ABCL-942: Pola-R-Mini-CHP for Untreated Diffuse Large B-Cell Lymphoma in Patients Who Are Elderly With Comorbid Conditions
2个月前
已关闭
Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial
2个月前
已完结
Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell Lymphoma
2个月前
已完结
ALPPS的研究现状与进展
2个月前
已完结
Liver Vein Deprivation: Rationale, Technique, and Review of the Literature
2个月前
已完结
Cost-effectiveness analysis of glofitamab versus rituximab for relapsed or refractory diffuse large B-cell lymphoma patients in China
2个月前
已完结
Recent advances in CD5+ diffuse large B-cell lymphoma
2个月前
已完结
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study
2个月前
已完结
皖公网安备34019202002308
